Business Context and Reporting Period
This Form 8-K filing by Myriad Genetics, Inc. (MYGN) was submitted on September 29, 2025, reporting events occurring on that date and effective dates in late September and early October 2025. The filing addresses significant changes in the Company's executive leadership regarding its principal accounting officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Departure of Principal Accounting Officer: Natalie Munk, Senior Vice President and Chief Accounting Officer, resigned effective October 24, 2025. The Company states her departure is not due to any disagreement regarding operations, policies, or practices.
- Appointment of Principal Accounting Officer: The Board designated Benjamin R. Wheeler, the Company's Chief Financial Officer (since August 2025), to serve as the new Principal Accounting Officer effective upon Ms. Munk's departure.
Management Commentary and Risks
Management confirmed that Mr. Wheeler received no additional compensation for his new designation and that no undisclosed arrangements or family relationships exist regarding his appointment. Mr. Wheeler brings over 13 years of experience at the Company, including previous roles in accounting and controllership, and holds a CPA designation. No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the transition timeline for the Principal Accounting Officer role between October 24, 2025, and the effective date of Mr. Wheeler's appointment.
- Confirm that the resignation of Ms. Munk has no undisclosed implications for ongoing audits or regulatory compliance.
- Review subsequent filings for any impact on the Company's internal controls over financial reporting due to this leadership change.